Satellos Bioscience Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MSCLF research report →
About the company
Satellos Bioscience Inc. , a company dedicated to regenerative medicine, focuses on pioneering treatments for various degenerative muscle conditions. A cornerstone of their research is a leading program aimed at developing an orally administered drug.
- CEO
- Francis Gleeson
- IPO
- 2012
- Employees
- 14
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $96.62M
- P/E
- -1.75
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- -5.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.42%
- ROIC
- -20.67%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,873,000 · -88419.16%
- EPS
- $-20.40 · -679900.00%
- Op Income
- $-26,459,000
- FCF YoY
- 5.52%
- 52W High
- $12.50
- 52W Low
- $0.88
- 50D MA
- $7.34
- 200D MA
- $6.08
- Beta
- 0.71
- Avg Volume
- 12.13K
Get TickerSpark's AI analysis on MSCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MSCLF coverage
Recent articles, reports, and earnings notes.
No research on MSCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MSCLF report →Similar companies
Peers in the same neighborhood.